Gadolinium-based compounds induce NLRP3-dependent IL-1βs production and peritoneal inflammation

Annals of the Rheumatic Diseases

Volumn 74, Issue 11, 2015, Pages 2062-2069

  Schmidt Lauber, Christian ^a   Bossaller, Lukas ^a   Abujudeh, Hani H ^b   Vladimer, Gregory I ^a   Christ, Anette ^a   Fitzgerald, Katherine A ^a   Latz, Eicke ^a,c   Gravallese, Ellen M ^a   Marshak Rothstein, Ann ^a   Kay, Jonathan ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; CRYOPYRIN; GADOLINIUM; GADOLINIUM BASED CONTRAST AGENT; GADOLINIUM CHLORIDE; GADOLINIUM PENTETATE; GAMMA INTERFERON; INFLAMMASOME; INTERLEUKIN 4; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CARRIER PROTEIN; GADODIAMIDE; IL1B PROTEIN, MOUSE; INTERLEUKIN 1BETA; NLRP3 PROTEIN, MOUSE; ORGANOMETALLIC COMPOUND; PYCARD PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CELL ACTIVATION; CELL POLARITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; IMMUNOREGULATION; INFLAMMATION; INFLAMMATORY CELL; MACROPHAGE; MALE; MONOCYTE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERITONEAL DISEASE; PERITONEAL INFLAMMATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; NEPHROGENIC SYSTEMIC FIBROSIS; PERITONEUM; PERITONITIS; SECRETION (PROCESS);

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; GADOLINIUM; GADOLINIUM DTPA; INFLAMMASOMES; INTERLEUKIN-1BETA; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEPHROGENIC FIBROSING DERMOPATHY; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; ORGANOMETALLIC COMPOUNDS; PERITONEUM; PERITONITIS;

EID: 84945179524     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204900     Document Type: Article

References (56)

1. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356:1000-1.
2. Moschella SL, Kay J, Mackool BT, et al. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med 2004;351:2219-27.
3. Girardi M, Kay J, Elston DM, et al. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 2011;65:1095-106.
4. Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001;23:383-93.
5. Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor β1 expression in affected skin. Arthritis Rheum 2004;50:2660-6.
6. Koreishi AF, Nazarian RM, Saenz AJ, et al. Nephrogenic systemic fibrosis: a pathologic study of autopsy cases. Arch Pathol Lab Med 2009;133:1943-8.
7. Kay J, Bazari H, Avery LL, et al. Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin. N Engl J Med 2008;358:827-38.
8. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56:27-30.
9. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:21-6.
10. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37°C. Invest Radiol 2008;43:817-28.
11. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998;5:491-502.
12. Runge VM, Dickey KM, Williams NM, et al. Local tissue toxicity in response to extravascular extravasation of magnetic resonance contrast media. Invest Radiol 2002;37:393-8.
13. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67.
14. Wermuth PJ, Del Galdo F, Jimenez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 2009;60:1508-18.
15. Del Galdo F, Wermuth PJ, Addya S, et al. NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. Ann Rheum Dis 2010;69:2024-33.
16. Edward M, Quinn JA, Burden AD, et al. Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology 2010;256:735-43.
17. Piera-Velazquez S, Louneva N, Fertala J, et al. Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. Ann Rheum Dis 2010;69:2017-23.
18. Wermuth PJ, Jimenez SA. Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis. J Immunol 2012;189:318-27.
19. Stutz A, Golenbock DT, Latz E. Inflammasomes: too big to miss. J Clin Invest 2009;119:3502-11.
20. Postlethwaite AE, Raghow R, Stricklin GP, et al. Modulation of fibroblast functions by interleukin 1: increased steady-state accumulation of type I procollagen messenger RNAs and stimulation of other functions but not chemotaxis by human recombinant interleukin 1 á and β. J Cell Biol 1988;106:311-18.
21. Postlethwaite AE, Smith GN Jr., Lachman LB, et al. Stimulation of glycosaminoglycan synthesis in cultured human dermal fibroblasts by interleukin 1. Induction of hyaluronic acid synthesis by natural and recombinant interleukin 1s and synthetic interleukin 1 beta peptide 163-171. J Clin Invest 1989;83:629-36.
22. Bonniaud P, Margetts PJ, Ask K, et al. TGF-β and Smad3 signaling link inflammation to chronic fibrogenesis. J Immunol 2005;175:5390-5.
23. Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008;9:847-56.
24. Rathinam VA, Vanaja SK, Fitzgerald KA. Regulation of inflammasome signaling. Nat Immunol 2012;13:333-42.
25. 2+ and cAMP. Nature 2012;492:123-7.
26. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35.
27. Pelegrin P, Surprenant A. Dynamics of macrophage polarization reveal new mechanism to inhibit IL-1β release through pyrophosphates. EMBO J 2009;28:2114-27.
28. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity 2005;23:344-6.
29. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 2010;32:593-604.
30. Sica A, Schioppa T, Mantovani A, et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006;42:717-27.
31. Lappalainen U, Whitsett JA, Wert SE, et al. Interleukin-1β causes pulmonary inflammation, emphysema, and airway remodeling in the adult murine lung. Am J Respir Cell Mol Biol 2005;32:311-18.
32. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464:1357-61.
33. Nakahira K, Haspel JA, Rathinam VA, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 2011;12:222-30.
34. Farina GA, York MR, Di Marzio M, et al. Poly (I: C) drives type I IFN- and TGFβ-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. J Invest Dermatol 2010;130:2583-93.
35. Guma M, Ronacher L, Liu-Bryan R, et al. Caspase 1-independent activation of interleukin-1β in neutrophil-predominant inflammation. Arthritis Rheum 2009;60:3642-50.
36. Bossaller L, Chiang PI, Schmidt-Lauber C, et al. Cutting Edge: FAS (CD95) mediates noncanonical IL-1β and IL-18 maturation via caspase-8 in an RIP3-Independent manner. J Immunol 2012;189:5508-12.
37. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011;11:723-37.
38. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009;27:451-83.
39. Guarda G, Braun M, Staehli F, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011;34:213-23.
40. Mishra BB, Rathinam VA, Martens GW, et al. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1β. Nat Immunol 2013;14:52-60.
41. Masters SL, Mielke LA, Cornish AL, et al. Regulation of interleukin-1β by interferon-γ is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin-17 production. EMBO Rep 2010;11:640-6.
42. Kay J, Czirjak L. Gadolinium and systemic fibrosis: guilt by association. Ann Rheum Dis 2010;69:1895-7.
43. Steger-Hartmann T, Raschke M, Riefke B, et al. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis-a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp Toxicol Pathol 2009;61:537-52.
44. Tan AW, Tan SH, Lian TY, et al. A case of nephrogenic fibrosing dermopathy. Ann Acad Med Singapore 2004;33:527-9.
45. Chaudhuri V, Zhou L, Karasek M. Inflammatory cytokines induce the transformation of human dermal microvascular endothelial cells into myofibroblasts: a potential role in skin fibrogenesis. J Cutan Pathol 2007;34:146-53.
46. Artlett CM, Sassi-Gaha S, Rieger JL, et al. The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum 2011;63:3563-74.
47. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41.
48. Cullen TH. Retroperitoneal fibroses - an association with hyperuricaemia. Br J Surg 1981;68:199-200.
49. Rimal B, Greenberg AK, Rom WN. Basic pathogenetic mechanisms in silicosis: current understanding. Curr Opin Pulm Med 2005;11:169-73.
50. Ishikawa O, Ishikawa H. Macrophage infiltration in the skin of patients with systemic sclerosis. J Rheumatol 1992;19:1202-6.
51. Saalbach A, Klein C, Schirmer C, et al. Dermal fibroblasts promote the migration of dendritic cells. J Invest Dermatol 2010;130:444-54.
52. Wermuth PJ, Jimenez SA. Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents. Clin Exp Immunol 2014;175:113-25.
53. Zheng XF, Hong YX, Feng GJ, et al. Lipopolysaccharide-induced M2 to M1 macrophage transformation for IL-12p70 production is blocked by Candida albicans mediated up-regulation of EBI3 expression. PLoS One 2013;8:e63967.
54. Ortiz LA, Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A 2007;104:11002-7.
55. Higashi-Kuwata N, Makino T, Inoue Y, et al. Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma. Exp Dermatol 2009;18:727-9.
56. Ikezumi Y, Suzuki T, Karasawa T, et al. Identification of alternatively activated macrophages in new-onset paediatric and adult immunoglobulin A nephropathy: potential role in mesangial matrix expansion. Histopathology 2011;58:198-210.